Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a2417c5a2b53b1a9

Jump to content

// Workers AI · dad joke modeWhat did CBS-0550 say to its friend? "You can count on me

From Wikipedia, the free encyclopedia
CBS-0550
Identifiers
  • N-[5-tert-butyl-2-(cyclopropylmethyl)-1-methylpyrazol-3-ylidene]-2-fluoro-3-(trifluoromethyl)benzamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H23F4N3O
Molar mass397.418 g·mol−1
3D model (JSmol)
  • C3CC3Cn1c(cc(C(C)(C)C)n1C)=N\C(=O)c2cccc(C(F)(F)F)c2F
  • InChI=1S/C20H23F4N3O/c1-19(2,3)15-10-16(27(26(15)4)11-12-8-9-12)25-18(28)13-6-5-7-14(17(13)21)20(22,23)24/h5-7,10,12H,8-9,11H2,1-4H3/b25-16+
  • Key:PABOWKPYVAFTRN-PCLIKHOPSA-N

CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB2 receptor agonist, with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects.[1] A number of related compounds have been developed with similar properties.[2]

See also

[edit]

References

[edit]
  1. Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Yamaguchi T, et al. (February 2008). "Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action". Bioorganic & Medicinal Chemistry. 16 (3): 1111–24. doi:10.1016/j.bmc.2007.10.087. PMID 18006322.
  2. Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Tomishima Y, et al. (November 2007). "N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability". Bioorganic & Medicinal Chemistry Letters. 17 (22): 6299–304. doi:10.1016/j.bmcl.2007.09.004. PMID 17884496.